相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
James L. Rubenstein et al.
BLOOD (2013)
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
Miroslav Dostalek et al.
CLINICAL PHARMACOKINETICS (2013)
At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity
Anne Danielou-Lazareth et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
Luca Bologna et al.
JOURNAL OF IMMUNOLOGY (2013)
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
David Cunningham et al.
LANCET (2013)
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial
Richard Delarue et al.
LANCET ONCOLOGY (2013)
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Molestias Onco-Hematologicas retrospective study
Angelo M. Carella et al.
LEUKEMIA & LYMPHOMA (2013)
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
Christian Klein et al.
MABS (2013)
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Sally Wenzel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Isotype and glycoform selection for antibody therapeutics
Roy Jefferis
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
Myron S. Czuczman et al.
BLOOD (2012)
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
Gilles Salles et al.
BLOOD (2012)
Aphase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
Laurie H. Sehn et al.
BLOOD (2012)
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
Carsten Mueller et al.
BLOOD (2012)
Properties of mouse and human IgG receptors and their contribution to disease models
Pierre Bruhns
BLOOD (2012)
Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma
David Ternant et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Combinatorial Chemotherapeutic Efficacy in Non-Hodgkin Lymphoma Can Be Predicted by a Signaling Model of CD20 Pharmacodynamics
John M. Harrold et al.
CANCER RESEARCH (2012)
A Guide to Rational Dosing of Monoclonal Antibodies
Shuang Bai et al.
CLINICAL PHARMACOKINETICS (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response
Ulrich Jaeger et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia
Jing Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Novel CD20 monoclonal antibodies for lymphoma therapy
Shundong Cang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
Frank J. Beurskens et al.
JOURNAL OF IMMUNOLOGY (2012)
Lepidopteran cells An alternative for the production of recombinant antibodies?
Martine Cerutti et al.
MABS (2012)
Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice
Rong Deng et al.
MABS (2012)
Setting the stage for biosimilar monoclonal antibodies
Christian K. Schneider et al.
NATURE BIOTECHNOLOGY (2012)
Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats
Leonid Kagan et al.
PHARMACEUTICAL RESEARCH (2012)
Monoclonal antibody (mAb)-based cancer therapy Is it time to reevaluate dosing strategies?
Margaret A. Lindorfer et al.
ONCOIMMUNOLOGY (2012)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
Waleed Alduaij et al.
BLOOD (2011)
The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab
Manfred Ahlgrimm et al.
BLOOD (2011)
Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies
Guillaume Cartron et al.
CLINICAL CANCER RESEARCH (2011)
Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
Luca Bologna et al.
JOURNAL OF IMMUNOLOGY (2011)
Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells
Paul V. Beum et al.
JOURNAL OF IMMUNOLOGY (2011)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al.
LANCET (2011)
Monoclonal antibodies in neuro-oncology Getting past the blood-brain barrier
Lois A. Lampson
MABS (2011)
Neonatal Fc receptor and IgG-based therapeutics
Timothy T. Kuo et al.
MABS (2011)
Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death
Josee Golay et al.
BLOOD (2010)
Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation
Hisayuki Yokoyama et al.
BLOOD (2010)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
Riad Abes et al.
BLOOD (2010)
Rituximab A Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Gillian M. Keating
DRUGS (2010)
Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia
Georg Aue et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
Stephen A. Beers et al.
SEMINARS IN HEMATOLOGY (2010)
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
E. C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
In vivo Model of Follicular Lymphoma Resistant to Rituximab
Stephane Dalle et al.
CLINICAL CANCER RESEARCH (2009)
Safety Assessment and Dose Selection for First-in-Human Clinical Trials With Immunomodulatory Monoclonal Antibodies
P. Y. Muller et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Novel targeted therapies for autoimmunity
E. William St Clair
CURRENT OPINION IN IMMUNOLOGY (2009)
Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials
Diane D. Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
M2 Macrophages phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro
Marzia Leidi et al.
JOURNAL OF IMMUNOLOGY (2009)
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
Andrew W. Pawluczkowycz et al.
JOURNAL OF IMMUNOLOGY (2009)
Structural Difference in the Complement Activation Site of Human IgG1 and IgG3
T. E. Michaelsen et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2009)
Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Royston Jefferis
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies
Julien Lejeune et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Siao-Yi Wang et al.
BLOOD (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
Paolo Macor et al.
CANCER RESEARCH (2007)
A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone
Minna Taskinen et al.
CLINICAL CANCER RESEARCH (2007)
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
Christoph Kahl et al.
BLOOD (2007)
Phase I to III trials of anti-b cell therapy in non-Hodgkin's lymphoma
Peter Martin et al.
CLINICAL CANCER RESEARCH (2007)
FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab
Emanuela Carlotti et al.
HAEMATOLOGICA (2007)
Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types
Yutaka Kanda et al.
GLYCOBIOLOGY (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
Modulation of therapeutic antibody effector functions by glycosylation engineering:: Influence of Golgi enzyme localization domain and co-expression of heterologous β1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II
C Ferrara et al.
BIOTECHNOLOGY AND BIOENGINEERING (2006)
Pharmacokinetic behavior of rituximab - A study of different schedules of administration for heterogeneous clinical settings
MB Regazzi et al.
THERAPEUTIC DRUG MONITORING (2005)
Lymphatic absorption is the primary contributor to the systemic availability of epoetin alfa following subcutaneous administration to sheep
DN McLennan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders
LN Gordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical pharmacokinetics of cyclophosphamide
ME de Jonge et al.
CLINICAL PHARMACOKINETICS (2005)
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia
AD Kennedy et al.
JOURNAL OF IMMUNOLOGY (2004)
FcγRIIIa and Fc-γRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
SS Farag et al.
BLOOD (2004)
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:: results of the NHL-B2 trial of the DSHNHL
M Pfreundschuh et al.
BLOOD (2004)
Rituximab-dependent cytotoxicity by natural killer cells:: Influence of FCGR3A polymorphism on the concentration-effect relationship
S Dall'Ozzo et al.
CANCER RESEARCH (2004)
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy
JJ Uchida et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
From the bench to the bedside: ways to improve rituximab efficacy
G Cartron et al.
BLOOD (2004)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Complement activation determines the therapeutic activity of rituximab in vivo
N Di Gaetano et al.
JOURNAL OF IMMUNOLOGY (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
CD20-mediated apoptosis: signalling through lipid rafts
JP Deans et al.
IMMUNOLOGY (2002)
Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab
H Pels et al.
JOURNAL OF NEURO-ONCOLOGY (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Complement activation plays a key role in the side-effects of rituximab treatment
LE van der Kolk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay et al.
BLOOD (2001)
Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)
H Milgrom et al.
PEDIATRICS (2001)
Complement activation in circulation and central nervous system after Rituximab (Anti-CD20) treatment of B-Cell lymphoma
A Harjunpää et al.
LEUKEMIA & LYMPHOMA (2001)
Engineered antibodies with increased activity to recruit complement
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2001)
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
